Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis.
Okusaka T, Nakamura M, Yoshida M, Kitano M, Ito Y, Mizuno N, Hanada K, Ozaka M, Morizane C, Takeyama Y; Committee for Revision of Clinical Guidelines for Pancreatic Cancer of the Japan Pancreas Society. Okusaka T, et al. Among authors: ozaka m. Int J Clin Oncol. 2023 Apr;28(4):493-511. doi: 10.1007/s10147-023-02317-x. Epub 2023 Mar 15. Int J Clin Oncol. 2023. PMID: 36920680 Free PMC article.
[Successful treatment with cetuximab combination chemotherapy in a case of FOLFOX-refractory rectal cancer with previously unresectable multiple liver metastases leading to complete resection].
Mitsuhashi K, Matsusaka S, Mizunuma N, Ichimura T, Ozaka M, Ogura M, Shinozaki E, Suenaga M, Chin K, Fujimoto Y, Saiura A, Yamamoto N, Hatake K. Mitsuhashi K, et al. Among authors: ozaka m. Gan To Kagaku Ryoho. 2010 Nov;37(11):2203-7. Gan To Kagaku Ryoho. 2010. PMID: 21084828 Japanese.
Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study).
Ozaka M, Matsumura Y, Ishii H, Omuro Y, Itoi T, Mouri H, Hanada K, Kimura Y, Maetani I, Okabe Y, Tani M, Ikeda T, Hijioka S, Watanabe R, Ohoka S, Hirose Y, Suyama M, Egawa N, Sofuni A, Ikari T, Nakajima T. Ozaka M, et al. Cancer Chemother Pharmacol. 2012 May;69(5):1197-204. doi: 10.1007/s00280-012-1822-1. Epub 2012 Jan 17. Cancer Chemother Pharmacol. 2012. PMID: 22249272 Clinical Trial.
Lack of associations between genetic polymorphisms in GSTM1, GSTT1 and GSTP1 and pancreatic cancer risk: a multi-institutional case-control study in Japan.
Yamada I, Matsuyama M, Ozaka M, Inoue D, Muramatsu Y, Ishii H, Junko U, Ueno M, Egawa N, Nakao H, Mori M, Matsuo K, Nishiyama T, Ohkawa S, Hosono S, Wakai K, Nakamura K, Tamakoshi A, Kuruma S, Nojima M, Takahashi M, Shimada K, Yagyu K, Kikuchi S, Lin Y. Yamada I, et al. Among authors: ozaka m. Asian Pac J Cancer Prev. 2014;15(1):391-5. doi: 10.7314/apjcp.2014.15.1.391. Asian Pac J Cancer Prev. 2014. PMID: 24528063 Free article.
Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies.
Yanagimoto H, Ishii H, Nakai Y, Ozaka M, Ikari T, Koike K, Ueno H, Ioka T, Satoi S, Sho M, Okusaka T, Tanaka M, Shimokawa T, Kwon AH, Isayama H. Yanagimoto H, et al. Among authors: ozaka m. J Hepatobiliary Pancreat Sci. 2014 Oct;21(10):761-6. doi: 10.1002/jhbp.130. Epub 2014 Jun 13. J Hepatobiliary Pancreat Sci. 2014. PMID: 24925464 Clinical Trial.
140 results